Marek J Romanowski, 65605 Suffolk Dr, Tucson, AZ 85704

2003005, Mar 27, 2003

Jun 6, 2002

10/165867

Evan Unger - Tucson AZ, US
Marek Romanowski - Tucson AZ, US
VaradaRajan Ramaswami - Tucson AZ, US

A61K031/4745
A61K009/127
A61K009/20
A61K009/14

424/465000, 424/486000, 514/283000

Pharmaceutical formulations are provided that increase the systemic bioavailability of camptotheca derivatives; preferably, the camptothecin derivative is 7-ethyl-10-hydroxyl camptothecin, SN-38. The drug is complexed with a stabilizing agent, but is not covalently bound thereto. Anionic or neutral lipids and/or polymers are used as the stabilizing agent, and secondary stabilizing agents and/or other excipients may be incorporated into the formulation as well. Therapeutic methods are also provided, wherein a formulation of the invention is administered to a patient to treat a condition, disorder, or disease that is responsive to camptothecin derivatives. Generally, administration is oral or parenteral.

2004000, Jan 15, 2004

Jun 5, 2003

10/457068

Evan Unger - Tucson AZ, US
Marek Romanowski - Tucson AZ, US
VaradaRajan Ramaswami - Tucson AZ, US
Reena Zutshi - Tucson AZ, US
Rachel LaBell - Vail AZ, US
Elizabeth Pigman - Tucson AZ, US

A61K031/4745
A61K009/14

424/486000, 514/283000

Pharmaceutical formulations are provided that increase the systemic bioavailability of camptotheca derivatives; preferably, the camptothecin derivative is 7-ethyl-10-hydroxyl camptothecin, SN-38. The drug is complexed with a stabilizing agent, but is not covalently bound thereto. Anionic or neutral lipids and/or polymers are used as the stabilizing agent, and secondary stabilizing agents and/or other excipients may be incorporated into the formulation as well. Therapeutic methods are also provided, wherein a formulation of the invention is administered to a patient to treat a condition, disorder, or disease that is responsive to camptothecin derivatives. Generally, administration is oral or parenteral.

2002004, Apr 11, 2002

Jul 25, 2001

09/912609

Evan Unger - Tucson AZ, US
Terry Matsunaga - Tucson AZ, US
Varadarajan Ramaswami - Tucson AZ, US
Marek Romanowski - Tucson AZ, US

A61K009/14
A61K039/395

424/486000, 424/178100

Novel targeted delivery systems for bioactive agents. In preferred form, the delivery systems comprise, in combination with an effective amount of a bioactive agent, a targeted matrix comprising a polymer and a targeting ligand. Preferably, the targeting ligand is covalently associated with the polymer and the bioactive agent is associated non-covalently with the polymer. Also in preferred embodiments, the bioactive agent is substantially homogeneously dispersed throughout the matrix. The compositions are particularly suitable as delivery vehicles with bioactive agents that have limited water solubility.

2020026, Aug 27, 2020

Jan 23, 2017

16/066265

- Tucson AZ, US
Marek Romanowski - Tucson AZ, US

A61B 5/00
A61B 5/03
A61B 5/0488
A61B 3/11
A61B 3/14

An ocular cranial nerve monitoring system (OCNMS) that provides continuous measurement of pupillary reactivity in the eye. The system features a sensor component that produces a stimulating light and a recording light and records reflected recording light so as to calculate pupillary diameter and response to stimulation as measured by latency, velocity, and/or amplitude. This system of the present invention may be used for indirect assessment of the 2nd and 3rd cranial nerve (CN 2, CN3) pathways and/or intracranial pressure in patients and may be used intraoperatively. The data obtained from this system may allow for immediate corrective actions, which may help prevent permanent deficits and improve patient safety and surgical outcomes. In some instances, the system may help avoid unnecessary or invasive procedures (e.g., catheters inserted for intracranial pressure monitoring).